Revenue (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Schedule of disaggregation of revenue

The following table and descriptions below show the products from which the Company generated its revenue for the periods indicated:

	Three Months Ended September 30,				Nine Months Ended September 30,
Revenue by product (in thousands)	2023		2022		2023		2022
MACI implants and kits
Implants based on contracted rate sold through a specialty pharmacy (a)	$	22,598	$	19,377	$	68,220	$	50,718
Implants subject to third party reimbursement sold through a specialty pharmacy (b)	5,030		4,207		13,526		12,015
Implants sold direct based on contracted rates (c)	5,797		6,457		19,932		17,846
Implants sold direct subject to third-party reimbursement (d)	1,432		898		2,974		2,331
Biopsy kits - direct bill	457		498		1,517		1,565
Change in estimates related to prior periods (e)	2,275		(428)		1,945		1,142
Total MACI implants and kits	37,589		31,009		108,114		85,617
Epicel
Direct bill (hospital)	7,394		7,317		23,808		25,387
NexoBrid (f)	598		225		598		667
Total revenue	$	45,581	$	38,551	$	132,520	$	111,671
(a) Represents implants sold through Orsini and AllCare whereby such specialty pharmacies have a direct contract with the underlying insurance provider. The amount of reimbursement is based on contracted rates at the time of sale supported by the pharmacy’s direct contracts.
(b) Represents implants sold through Orsini and AllCare whereby such specialty pharmacy does not have a direct contract with the underlying payer, and are subject to third-party reimbursement. The amount of reimbursement is established based on publicly available rates, fee schedules or past payer precedents.
(c) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. Also represents direct sales under a contract to specialty distributor DMS.
(d) Represents implants sold directly from the Company to the facility based on a contract and known price agreed upon prior to the surgery date. The payment terms are subject to third-party reimbursement from an underlying insurance provider.
(e) Primarily represents changes in estimates related to implants sold through Orsini or AllCare and relate to changes to the initial expected reimbursement or collection expectations upon completion of the billing claims process. The change in estimates is a result of additional information, changes in collection expectations or actual cash collections received in the current period.
(f) Represents commercial revenue for the three and nine months ended September 30, 2023. Represents revenue based on a percentage of gross profits for sales of NexoBrid to BARDA, pursuant to the license agreement between the Company and MediWound, in the three and nine months ended September 30, 2022 (see Note 11).